Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Health disparity in hematopoietic cell transplantation for sickle cell disease: Analyzing the association of insurance and socioeconomic status among children undergoing hematopoietic cell transplantation
source: American Society of Hematology
year: 2017
authors: Sonia Anand, Rodney Theodore, Ann Mertens, Peter A. Lane, Lakshmanan Krishnamurti
summary/abstract:The impact of racial and socioeconomic status (SES) on access to hematopoietic cell transplantation (HCT) are well known. Even when controlled for SES, racial minorities have lower access to HCT than the racial majority groups. Since the majority of patients with sickle cell disease (SCD) in the US are of African descent, HCT for SCD provides a unique opportunity to study the impact of SES on access to HCT in a relatively uniform racial population. The objectives of this study were to explore whether insurance status and SES are associated with the HCT for SCD.
Methods: The clinical database from the SCD program at Children’s Healthcare of Atlanta (CHOA), which contains over 3,100 patients, was used to identify SCD patients who have undergone HCT between January 1, 2012 and December 31, 2016 at CHOA. We then identified non-transplanted SCD patients matched for age at transplant, gender, and SCD genotype. Three matched controls were randomly selected for each case except for one older patient who only had two controls. Non-Georgia residents during the year of transplant were excluded; one sickle cell patient who had BMT due to acute lymphoblastic leukemia was also excluded. Among both the transplanted patients and their controls, insurance status was assessed as well as socioeconomic status was estimated based on block-level census data, specifically household income, home value, percent single parent households, percent unemployment, and education level. Conditional logistic regression analysis using backwards elimation was performed to determine the odds of receiving HCT.
Results: Of 34 patients with SCD who underwent HCT at CHOA during this time period, 27 (66.7% females and 33.3% males) were Georgia residents. Twenty-five of the 27 patients received a matched-sibling donor transplant and two had matched-unrelated donor transplant. Among the HCT patients, the median age at transplant was 8 ± 4.7 years (range 1-20 yr). Of the 27 HCT patients, 59.3% had Medicaid and 40.7% had Private insurance at the time of transplant. Among the controls, 81.3% were covered by Medicaid insurance, 17.5% with Private insurance, and 1.3% self-pay. Using a conditional logistic regression model, we found insurance status to be a statistically significant factor in predicting whether a patient undergoes HCT. The model showed that those with Private Insurance are 2.96 (95% Confidence Interval: 1.02, 8.54) times more likely to undergo HCT compared to patients with Medicaid and self-pay. No other socioeconomic status variables were associated with receiving HCT.
organization: Childrens Healthcare of Atlanta, Atlanta, GA; Emory University School of Medicine, Atlanta, GAread more
+myBinderRelated Content
-
Early occurrence of red blood cell alloimmunization in patients with sickle cell diseaseRed blood cell (RBC) alloimmunization is...
-
9-year-old violin prodigy defeats strokes, paralysis; raising money for bone-marrow transplantAt age 4, musical prodigy Caesar Sant co...
-
Assessing the safety and efficacy of converting adults with sickle cell disease from full agonist opioids to bupreno...Background: The management of pain in ad...
-
Tionne ‘T-Boz’ Watkins to dish on her Incurable disease, TLC Stardom and left eye’s death in new m...Many storms have come and gone...
-
Gene-Editing Treatment Shows Promise for Sickle Cell DiseaseScientists are seeing promising early re...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
-
The Ways I Made Hydration a HabitWhen I was younger and didn’t have a f...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.